Andrew J K Ostor (Andrew Östör, Andrew J Östör)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Ankylosing Spondylitis

Anti Inflammatory Drugs

Top Venues

Rheumatology and therapy

Rheumatology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim A Papp, Cecilia Asnal, Ricardo Blanco-Alonso, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M Soliman, Michael M Chen, Byron Padilla, Alan J Kivitz
Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial. Rheumatology and therapy 11 (3) (2024)
Andrew J K Ostor, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Byron Padilla, Alan Kivitz
Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study. Rheumatology (Oxford, England) (2022)
Désirée Mfm van der Heijde, Atul Deodhar, Walter P Maksymowych, Joachim Sieper, Filip Van den Bosch, Tae Hwan Kim, Kishimoto Mitsumasa, Andrew J K Ostor, Bernard Combe, Yunxia Sui, Yuanyuan Duan, Peter K Wung, In-Ho Song
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension. RMD open 8 (2) (2022)
Andrew J K Ostor, Ahmed M Soliman, Kim A Papp, Byron Padilla, Zailong Wang, Ann Eldred, Kurt de Vlam, Alan Kivitz
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2. RMD open 8 (2) (2022)
Iain B McInnes, Andrew J K Ostor, Phillip J Mease, William Tillett, Xenofon Baraliakos, Kurt de Vlam, Louis Bessette, Ralph Lippe, Anna Maniccia, Dai Feng, Tianming Gao, Patrick Zueger, Christopher Saffore, Koji Kato, In-Ho Song, Atul Deodhar
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD open 8 (1) (2022)